All Oncology News

Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.

Three researchers from Dana-Farber Cancer Institute have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.

TLX101 was associated with a favorable safety profile and preliminary signs of clinical activity in patients with recurrent high-grade glioma.

A new drug application for zurletrectinib has been accepted in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for renal cell carcinoma.

Nerea Lopetegui-Lia, MD, discusses the prevalence of and risk factors for triple-negative breast cancer, and strategies that may improve survival outcomes.

Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.

Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

A sBLA for nogapendekin alfa inbakicept in BCG-unresponsive non–muscle-invasive bladder cancer with papillary disease was submitted to the FDA.

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

Sylvester Comprehensive Cancer Center has opened a clinical trial for patients with high-grade neuroendocrine cancers evaluating an oncolytic virus.

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.

Patients with MCL who received real-world brexu-cel experienced lower survival when they were BTK inhibitor refractory and/or had lower platelet counts.

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.

Apalutamide reduced the risk of death by over 20% vs enzalutamide and abiraterone acetate, respectively, in metastatic castration-sensitive prostate cancer.

The EC approved glofitamab with gemcitabine/oxaliplatin for patients with relapsed or refractory diffuse large B-cell lymphoma, ineligible for ASCT.

The FDA granted fast track designation to emactuzumab for unresectable tenosynovial giant cell tumor.

Maurie Markman, MD, discusses the potential to shift the focus of cancer research towards the "real high technology of medicine", such as cancer vaccines.

K. “Vish” Viswanath, PhD, of Dana-Farber Cancer Center, has been named Fellow of the American Association for the Advancement of Science.

Pamela T. Soliman, MD, MPH, discusses a phase 1 investigation of temsirolimus plus metformin in patients with recurrent endometrial cancer.

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.

PROs and gene expression in peripheral blood varied in patients with acute myeloid leukemia receiving induction chemotherapy.